Rallybio Corporation
RLYB
$0.2992
-$0.0017-0.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -32.52% | 40.47% | 221.08% | -- | -- |
| Gross Profit | 34.03% | -38.21% | -218.80% | -- | -- |
| SG&A Expenses | -27.82% | -27.35% | -21.97% | -14.19% | -6.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.73% | -10.16% | -0.15% | 7.10% | 16.27% |
| Operating Income | 27.54% | 10.96% | 0.55% | -7.10% | -16.27% |
| Income Before Tax | 22.52% | 5.04% | -4.76% | -9.79% | -11.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.52% | 5.04% | -4.76% | -9.79% | -11.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.52% | 5.04% | -4.76% | -9.79% | -11.87% |
| EBIT | 27.54% | 10.96% | 0.55% | -7.10% | -16.27% |
| EBITDA | 27.57% | 10.96% | 0.53% | -7.14% | -16.34% |
| EPS Basic | 27.36% | 11.75% | 8.17% | 8.67% | 12.48% |
| Normalized Basic EPS | 31.74% | 16.23% | 12.32% | 12.60% | 12.48% |
| EPS Diluted | 27.36% | 11.75% | 8.17% | 8.67% | 12.48% |
| Normalized Diluted EPS | 31.74% | 16.23% | 12.32% | 12.60% | 12.48% |
| Average Basic Shares Outstanding | 7.65% | 8.60% | 13.05% | 18.36% | 27.19% |
| Average Diluted Shares Outstanding | 7.65% | 8.60% | 13.05% | 18.36% | 27.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |